Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARCT
stocks logo

ARCT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
14.17M
-37.78%
-0.790
-28.83%
6.85M
-76.69%
-0.612
+17.69%
9.35M
-66.96%
-0.588
+72.94%
Estimates Revision
The market is revising Upward the revenue expectations for Arcturus Therapeutics Holdings Inc. (ARCT) for FY2025, with the revenue forecasts being adjusted by 0.86% over the past three months. During the same period, the stock price has changed by -61.74%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.86%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-21.48%
In Past 3 Month
Stock Price
Go Down
down Image
-61.74%
In Past 3 Month
Wall Street analysts forecast ARCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARCT is 31.29 USD with a low forecast of 9.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast ARCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARCT is 31.29 USD with a low forecast of 9.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 6.830
sliders
Low
9.00
Averages
31.29
High
72.00
Current: 6.830
sliders
Low
9.00
Averages
31.29
High
72.00
Citi
Yigal Nochomovitz
Neutral
downgrade
$12 -> $9
2025-11-13
Reason
Citi
Yigal Nochomovitz
Price Target
$12 -> $9
2025-11-13
downgrade
Neutral
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on Arcturus Therapeutics to $9 from $12 and keeps a Neutral rating on the shares.
Piper Sandler
Piper Sandler
Overweight
downgrade
$140 -> $72
2025-11-11
Reason
Piper Sandler
Piper Sandler
Price Target
$140 -> $72
2025-11-11
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Arcturus Therapeutics to $72 from $140 and keeps an Overweight rating on the shares after the company reported Q3 earnings and provided a comprehensive update across their ARCT-032 CF and ARCT-810 OTC deficiency programs. The company discussed that they are on track to reach regulatory alignment on a pivotal ARCT-810 OTC deficiency program in the first half of 2026 where there will likely be two separate conversations for adult and pediatric populations. In regard to KOSTAIVE, management noted the U.S. BLA filing has been delayed indefinitely due to regulatory changes and uncertain U.S. commercial viability with reduction of additional expenses. Thus, Piper views the first half of 2026 as an important inflection point for the name with updates expected across both CF and OTC programs.
H.C. Wainwright
Buy
to
Neutral
downgrade
$60 -> $12
2025-10-24
Reason
H.C. Wainwright
Price Target
$60 -> $12
2025-10-24
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright downgraded Arcturus Therapeutics to Neutral from Buy with a price target of $12, down from $60. The firm does not believe the company's cystic fibrosis program is worth progressing towards later stage clinical trials based on key opinion leader conversations regarding the interim Phase 2 ARCT-032 data. Arcturus would be better positioned to instead invest in early stage assets, the analyst tells investors in a research note.
Wells Fargo
Overweight -> NULL
downgrade
$42 -> $20
2025-10-23
Reason
Wells Fargo
Price Target
$42 -> $20
2025-10-23
downgrade
Overweight -> NULL
Reason
Wells Fargo lowered the firm's price target on Arcturus Therapeutics to $20 from $42 and keeps an Overweight rating on the shares. The firm Phase 2 data suggests establishing efficacy of inhaled mRNA may take more effort than expected. Wells does think mucus reduction data are intriguing, especially with anatomical consistency.
Citi
Yigal Nochomovitz
Buy -> Neutral
downgrade
$49 -> $12
2025-10-23
Reason
Citi
Yigal Nochomovitz
Price Target
$49 -> $12
2025-10-23
downgrade
Buy -> Neutral
Reason
Citi analyst Yigal Nochomovitz downgraded Arcturus Therapeutics to Neutral from Buy with a price target of $12, down from $49. The ARCT-032 Phase 2 trail did not show a meaningful improvement for cystic fibrosis patients despite high expectations, the analyst tells investors in a research note. Citi now sees challenged prospects for the drug's late-stage development.
Guggenheim
Buy
to
Neutral
downgrade
2025-10-22
Reason
Guggenheim
Price Target
2025-10-22
downgrade
Buy
to
Neutral
Reason
Guggenheim downgraded Arcturus Therapeutics to Neutral from Buy.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Arcturus Therapeutics Holdings Inc (ARCT.O) is -2.71, compared to its 5-year average forward P/E of -8.49. For a more detailed relative valuation and DCF analysis to assess Arcturus Therapeutics Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.49
Current PE
-2.71
Overvalued PE
-1.01
Undervalued PE
-15.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.28
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.06
Undervalued EV/EBITDA
-5.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.72
Current PS
0.00
Overvalued PS
29.33
Undervalued PS
-9.90
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ARCT News & Events

Events Timeline

(ET)
2025-11-10
16:02:57
Arcturus Therapeutics announces Q3 earnings per share of 49 cents, below consensus estimate of 80 cents.
select
2025-10-22 (ET)
2025-10-22
08:05:24
Arcturus Therapeutics reveals preliminary findings from ARCT-032 trial
select
2025-08-11 (ET)
2025-08-11
16:03:42
Arcturus Therapeutics reports Q2 EPS (34c), consensus (87c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-11SeekingAlpha
Arcturus Announces Launch of 12-Week Cystic Fibrosis Study in 2026, Facing Cost Management and KOSTAIVE BLA Delays

  • Management Insights: CEO Joseph Payne reported positive interim Phase II data for ARCT-032, an mRNA therapeutic for cystic fibrosis, and ARCT-810 for OTC deficiency, while also noting the indefinite delay of the KOSTAIVE COVID-19 vaccine's US BLA filing due to regulatory changes.

  • Financial Performance: CFO Andrew Sassine highlighted a significant revenue decline for Q3 2025, with total revenues of $17.2 million, and a net loss of approximately $13.5 million, while emphasizing the company's strong financial position with a cash runway extended into 2028.

  • Future Outlook: The company plans to initiate a 12-week study for ARCT-032 in the first half of 2026 and is preparing for regulatory meetings regarding pivotal trials for both CF and OTC programs, focusing on safety and efficacy data.

  • Risks and Concerns: Management acknowledged challenges due to sudden FDA regulatory changes affecting KOSTAIVE, alongside the need for further regulatory alignment for both therapeutic programs, while maintaining a focus on cost control and resource allocation.

[object Object]
Preview
7.0
11-10PRnewswire
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

  • Investigation Announcement: Edelson Lechtzin LLP is investigating Arcturus Therapeutics for potential violations of federal securities laws due to allegations of misleading business information provided to investors.

  • Stock Impact: Following the release of disappointing Phase 2 trial results for its inhaled mRNA therapy ARCT-032, Arcturus's stock plummeted by over 50%, closing at $11.54 per share.

  • Company Overview: Arcturus Therapeutics focuses on developing mRNA vaccines and therapies, highlighting its role in the biotechnology sector.

  • Legal Representation: Investors affected by the stock drop or with relevant non-public information are encouraged to contact Edelson Lechtzin LLP for potential legal assistance.

[object Object]
Preview
5.0
10-25TipRanks
Cathie Wood Reduces Holdings in AMD and Other U.S. Tech Stocks, Increases Investment in Baidu and Biotech Sectors

  • Portfolio Adjustments: ARK Invest's ETFs made significant changes on October 24, 2025, reducing holdings in high-valuation tech stocks like AMD, Shopify, and Palantir, while increasing positions in Baidu and biotech companies such as Pacific Biosciences and Arcturus Therapeutics.

  • Major Transactions: The ARK Innovation ETF (ARKK) sold large quantities of shares, including 23,717 shares of AMD and 39,077 shares of Shopify, indicating a strategy of profit-taking in the tech sector amid rising AI chip demand.

  • Focus on AI and Biotech: ARK's renewed interest in Baidu, with a purchase of over 51,000 shares, reflects confidence in the company's role in AI and autonomous driving, while continued investments in biotech firms highlight a commitment to genomic innovation.

  • Ongoing Trends: The ARK Genomic Revolution ETF (ARKG) also sold shares of Tempus AI, continuing a trend of reducing exposure in certain tech stocks while actively buying into next-generation sequencing technologies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Arcturus Therapeutics Holdings Inc (ARCT) stock price today?

The current price of ARCT is 6.83 USD — it has increased 3.64 % in the last trading day.

arrow icon

What is Arcturus Therapeutics Holdings Inc (ARCT)'s business?

Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

arrow icon

What is the price predicton of ARCT Stock?

Wall Street analysts forecast ARCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARCT is 31.29 USD with a low forecast of 9.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Arcturus Therapeutics Holdings Inc (ARCT)'s revenue for the last quarter?

Arcturus Therapeutics Holdings Inc revenue for the last quarter amounts to 17.15M USD, decreased -58.84 % YoY.

arrow icon

What is Arcturus Therapeutics Holdings Inc (ARCT)'s earnings per share (EPS) for the last quarter?

Arcturus Therapeutics Holdings Inc. EPS for the last quarter amounts to -0.49 USD, increased 88.46 % YoY.

arrow icon

What changes have occurred in the market's expectations for Arcturus Therapeutics Holdings Inc (ARCT)'s fundamentals?

The market is revising Upward the revenue expectations for Arcturus Therapeutics Holdings Inc. (ARCT) for FY2025, with the revenue forecasts being adjusted by 0.86% over the past three months. During the same period, the stock price has changed by -61.74%.
arrow icon

How many employees does Arcturus Therapeutics Holdings Inc (ARCT). have?

Arcturus Therapeutics Holdings Inc (ARCT) has 174 emplpoyees as of December 05 2025.

arrow icon

What is Arcturus Therapeutics Holdings Inc (ARCT) market cap?

Today ARCT has the market capitalization of 194.06M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free